Cardio-Oncology

Questions discussed in this category

For CLL patients with high-risk cytogenetics on ibrutinib who develop a cardiac event such as an MI, would you continue ibrutinib?

Would you continue ibrutinib even if they are placed on anti-platelet therapy such as clopidogrel or ticagrelor? When do you switch to an altern...

5 Answers available

What are your management strategies for malignant pericardial effusion with a high risk of spontaneous hemorrhage, particularly in patients requiring anticoagulation for chronic atrial fibrillation?

1 Answer available

How should you approach treating curable laryngeal cancer with chemo-RT in a patient who had a myocardial infarction during treatment and requires CABG, given the cardiotoxicity of cisplatin and 5FU/carboplatin?

4 Answers available

How do you advise patients on cardiotoxicity when they are expected to receive a low mean heart dose and low cardiac substructure doses with their radiation plan?

Such as breast plans with < 200 cGy mean heart dose

1 Answer available

How would you manage a cardiac metastasis from Merkel cell carcinoma?

The patient has an asymptomatic metastasis in the left atrial appendage. Would you start off with immunotherapy then add radiation later, or visa ver...

1 Answer available

What are your top takeaways from ACC 2024?

3 Answers available

Should all patients with a remote history of immunotherapy, chemotherapy and/or radiation therapy have a baseline TTE regardless of ASCVD risk?

2 Answers available

How do you manage patients blood pressures while on anti-angiogenic TKIs?

Do you insist on ambulatory/home blood pressures to rule in/out white coat hypertension? Does your practice have a system to log patients' BPs to supp...

1 Answer available

What, if any, cardioprotective measures beyond dexrazoxane may be used to minimize cardiac risk during or after chemo- or radio-therapy?

Are there other measures, pharmocologic or adjunctive, that can be used or are under investigation to mitigate cardiotoxicity related to chemo- or rad...

2 Answers available

Do you routinely check echocardiograms on all patients who are starting TDM1?

1 Answer available

How do you manage severe hypertriglyceridemia in the adolescent & young adult population receiving chemotherapy for ALL, in the absence of complications related to hypertriglyceridemia?

1 Answer available

Would you favor PCI or CABG for younger patients with radiation-associated cardiac disease in the absence of any significant valvular abnormalities?

For radiation oncologists, how do you ameliorate the risk for radiation-related injury to epicardial coronaries during treatment sessions?

2 Answers available

Can CAR T cell therapy be considered for heart transplant recipients with concurrent lymphoproliferative disorders?

1 Answer available

Would you recommend that hematologists test for clonal hematopoiesis of indeterminate potential (CHIP) in patients with an intermediate 10-year risk of ASCVD?

Is the data compelling enough to merit intensifying or initiating primary prevention if the patient has CHIP?

1 Answer available

How do you approach a patient with newly diagnosed high-grade osteosarcoma who received maximum cumulative dose of doxorubicin for a soft tissue sarcoma 10 years earlier?

3 Answers available

Would you offer capecitabine re-challenge for a patient with metastatic breast cancer and a history of coronary vasospasm?

If so, under what circumstances?

1 Answer available

Should patients with co-existing moderate-severe valvular disease (particularly AS and MS) and malignancy requiring radiation therapy undergo more frequent surveillance surface echocardiograms?

1 Answer available

For patients on immune checkpoint inhibitors presenting with chest pain, dyspnea, fatigue, and troponin elevation, would you recommend early initiation of high dose steroids for empiric treatment of ICI myocarditis while pursuing workup with coronary angiogram, echocardiogram, and/or cardiac MRI, or wait until alternative etiologies have been ruled out?

2 Answers available

Is there any role for palliative radiation in the treatment of pericardial metastases?

Assuming the patient is symptomatic and/or has compression of ventricles, what field design and dose-fractionation would you use?

2 Answers available

Do you ever initiate on degarelix and then switch to leuprolide for patients with prostate cancer and cardiac risk factors receiving ADT?

If so, how long are they on degarelix before the switch?

2 Answers available

What is your surveillance approach for outpatient monitoring of ICI myocarditis?

(i.e. frequency of serial BNP, troponin, cMRI)

2 Answers available

Given recent studies investigating ICI myocarditis biomarkers such as Temra CD8+ cells, is there now a growing selection of clinical biomarkers, besides BNP and troponin, being measured routinely in ICI myocarditis cases?

2 Answers available

When would you consider tapering glucocorticoids in a patient with ICI-associated myocarditis?

2 Answers available

Is there a validated risk prediction model you favor to risk stratify patients for cardiotoxicity prior to initiation of chemotherapy?

1 Answer available

What radiation dose is a risk for damaging function or active leads from a pacemaker?

If the pacemaker receives no dose, what dose are the leads allowed to receive and still function? Should interrogation(s) be done weekly?Does dose per...

3 Answers available

Would you consider starting an ACE inhibitor on a patient without CVD or heart failure prior to initiation of anthracyclines to reduce the overall risk of myocardial toxicity?

2 Answers available

Would you consider using anthracycline for treating a Stage I triple negative breast cancer in a patient with a baseline mildly reduced LVEF 50-55%?

2 Answers available

Which molecular biomarkers do you favor to risk stratify patients (without CV risk factors) before and after undergoing treatment with cardiotoxic cancer treatments?

1 Answer available

Among asymptomatic patients with structurally normal TTE undergoing treatment with anthracyclines or alkylating agents that develop mildly elevated BNP and/or troponin levels, would you consider referring them for cardiac MRI to evaluate for subclinical cardiotoxicity?

1 Answer available